Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II durvalumab in mismatch repair deficient or POLE mutated metastatic colorectal cancer
KCT0002892Phase 2Completed
- Sponsor
- AstraZeneca
- Start
- Apr 2018
- Modality
- PD-1/PD-L1 Inhibitors → Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of durvalumab in metastatic colon cancer (mCRC), sponsored by AstraZeneca. Started Apr 2018; status: completed.
02
Drugs
durvalumab
03
Conditions
metastatic colon cancer (mCRC)
Beyond the preview
Go deeper on KCT0002892.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on KCT0002892.